Stay updated on AZD5991 and Venetoclax Combo in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the AZD5991 and Venetoclax Combo in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AZD5991 and Venetoclax Combo in Hematologic Malignancies Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:32:43.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to a multicenter, open-label, nonrandomized study assessing the safety, tolerability, and anti-tumor activity of AZD5991 alone or in combination with Venetoclax in subjects with relapsed or refractory hematologic malignancies.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:01.000Z thumbnail image
  7. Check
    26 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying the requirements for inclusion and exclusion in the study. This change provides comprehensive information about the health conditions and prior treatments needed for participation in the clinical trial.
    Difference
    48%
    Check dated 2024-05-22T21:10:03.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T21:58:38.000Z thumbnail image

Stay in the know with updates to AZD5991 and Venetoclax Combo in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AZD5991 and Venetoclax Combo in Hematologic Malignancies Clinical Trial page.